Halozyme Therapeutics reported $279.36M in Gross Profit on Sales for its fiscal quarter ending in June of 2025.


Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 243.83M 19.91M Jun/2025
Agios Pharmaceuticals USD 10.75M 3.11M Jun/2025
Alnylam Pharmaceuticals USD 630.74M 107.59M Jun/2025
Amarin USD 25.13M 1.78M Mar/2025
Amgen USD 6.17B 624M Jun/2025
Baxter International USD 1.14B 283M Jun/2025
Cytokinetics 66.77M 165.03M Jun/2025
DBV Technologies -30442000 30.56M Sep/2024
Eli Lilly USD 13.11B 2.61B Jun/2025
Halozyme Therapeutics USD 279.36M 62.9M Jun/2025
Ionis Pharmaceuticals USD 448M 317.85M Jun/2025
MannKind USD 1.89M 59.45M Jun/2025
Pfizer USD 10.88B 248M Jun/2025
United Therapeutics USD 711M 9.1M Jun/2025